Publications by authors named "Joseph P Balint"

Claim this Profile
A
Adenoviral vector-based vaccine is fully protective against lethal Lassa fever challenge in Hartley guinea pigs.
Junki Maruyama, Elizabeth J Mateer, John T Manning, Rachel Sattler, Alexey V Seregin, Joseph P Balint

Vaccine· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic.
Elizabeth S Gabitzsch, Kwong Yok Tsang, Claudia Palena, Justin M David, Massimo Fantini, Joseph P Balint

Oncotarget· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extended evaluation of a phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancer.
Joseph P Balint, Elizabeth S Gabitzsch, Adrian Rice, Yvette Latchman, Younong Xu

Cancer Immunol Immunother· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients.
Michael A Morse, Arvind Chaudhry, Elizabeth S Gabitzsch, Amy C Hobeika, Takuya Osada, Joseph P Balint

Cancer Immunol Immunother· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Induction and comparison of SIV immunity in Ad5 naïve and Ad5 immune non-human primates using an Ad5 [E1-, E2b-] based vaccine.
Elizabeth S Gabitzsch, Younong Xu, Joseph P Balint, Stephanie Balcaitis, Brigitte Sanders-Beer

Vaccine· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevention of influenza virus shedding and protection from lethal H1N1 challenge using a consensus 2009 H1N1 HA and NA adenovirus vector vaccine.
Frank R Jones, Elizabeth S Gabitzsch, Younong Xu, Joseph P Balint, Viktoriya Borisevich

Vaccine· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-tumor immunotherapy despite immunity to adenovirus using a novel adenoviral vector Ad5 [E1-, E2b-]-CEA.
Elizabeth S Gabitzsch, Younong Xu, Joseph P Balint, Zachary C Hartman, H Kim Lyerly

Cancer Immunol Immunother· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis